Blood:突变型钙网蛋白可通过促进TpoR转运,促进癌变的发生

2019-03-23 不详 MedSci原创

在骨髓及髓外增殖性肿瘤中,钙网蛋白 (CALR) 的第9个外显子上常发生移码突变(+1)。突变型CALRs具有一个新的C端序列,富含带正电荷的氨基酸,可以激活血小板生成素受体(TpoR/MPL)。Christian Pecquet等研究人员发现新序列使突变型CALR获得异常的伴侣蛋白活性,可稳定二聚体状态,并在无法通过质量控制的状态下将TpoR及其突变体运输到细胞表面,这一功能对于致癌转化至关重要

在骨髓及髓外增殖性肿瘤中,钙网蛋白 (CALR) 的第9个外显子上常发生移码突变(+1)。突变型CALRs具有一个新的C端序列,富含带正电荷的氨基酸,可以激活血小板生成素受体(TpoR/MPL)。

Christian Pecquet等研究人员发现新序列使突变型CALR获得异常的伴侣蛋白活性,可稳定二聚体状态,并在无法通过质量控制的状态下将TpoR及其突变体运输到细胞表面,这一功能对于致癌转化至关重要。突变型CALRs通过部分未成熟的TpoR的分泌途径来控制对TpoR的转运,可保护N117链糖基化不被高尔基体进一步加工。

突变型CALRs可以挽救许多加工的或与疾病相关的TpoRs的转运和功能,如导致先天性血小板减少的TpoR/MPL R102P,也可以克服TpoR上的内质网滞留信号。突变型CALRs除了需要TpoR N链糖基化,还需要TpoR胞外结构域上的疏水斑块诱导TpoR的热稳定性和胞内初始化激活,完全激活则需要TpoR定位在细胞表面。因此,突变型CALRs是TpoR和转运缺陷的TpoR突变体的恶性伴侣,可促进癌症的发生。



原始出处:

Christian Pecquet, et al.Calreticulin mutants as oncogenic rogue chaperones for TpoR and traffic-defective pathogenic TpoR mutants.http://www.bloodjournal.org/content/early/2019/03/22/blood-2018-09-874578

本文系梅斯医学(MedSci)原创编译,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2041381, encodeId=42282041381a7, content=<a href='/topic/show?id=baade55002a' target=_blank style='color:#2F92EE;'>#突变型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75500, encryptionId=baade55002a, topicName=突变型)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Sat Sep 28 08:46:00 CST 2019, time=2019-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1696333, encodeId=2265169633385, content=<a href='/topic/show?id=0107934e0a5' target=_blank style='color:#2F92EE;'>#转运#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93470, encryptionId=0107934e0a5, topicName=转运)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=47c429881595, createdName=yzh409, createdTime=Sat May 18 19:46:00 CST 2019, time=2019-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2036555, encodeId=79b820365556c, content=<a href='/topic/show?id=672b1e7029e' target=_blank style='color:#2F92EE;'>#TpoR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17702, encryptionId=672b1e7029e, topicName=TpoR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=69cb413, createdName=chengjn, createdTime=Mon Feb 24 03:46:00 CST 2020, time=2020-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1719432, encodeId=87781e1943229, content=<a href='/topic/show?id=72b8963e392' target=_blank style='color:#2F92EE;'>#钙网蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96373, encryptionId=72b8963e392, topicName=钙网蛋白)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=079632715693, createdName=nian.wang1993, createdTime=Tue May 14 00:46:00 CST 2019, time=2019-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1557078, encodeId=39cb155e0789a, content=<a href='/topic/show?id=154be128170' target=_blank style='color:#2F92EE;'>#癌变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71281, encryptionId=154be128170, topicName=癌变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cd7914850828, createdName=axin014, createdTime=Mon Mar 25 09:46:00 CST 2019, time=2019-03-25, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2041381, encodeId=42282041381a7, content=<a href='/topic/show?id=baade55002a' target=_blank style='color:#2F92EE;'>#突变型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75500, encryptionId=baade55002a, topicName=突变型)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Sat Sep 28 08:46:00 CST 2019, time=2019-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1696333, encodeId=2265169633385, content=<a href='/topic/show?id=0107934e0a5' target=_blank style='color:#2F92EE;'>#转运#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93470, encryptionId=0107934e0a5, topicName=转运)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=47c429881595, createdName=yzh409, createdTime=Sat May 18 19:46:00 CST 2019, time=2019-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2036555, encodeId=79b820365556c, content=<a href='/topic/show?id=672b1e7029e' target=_blank style='color:#2F92EE;'>#TpoR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17702, encryptionId=672b1e7029e, topicName=TpoR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=69cb413, createdName=chengjn, createdTime=Mon Feb 24 03:46:00 CST 2020, time=2020-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1719432, encodeId=87781e1943229, content=<a href='/topic/show?id=72b8963e392' target=_blank style='color:#2F92EE;'>#钙网蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96373, encryptionId=72b8963e392, topicName=钙网蛋白)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=079632715693, createdName=nian.wang1993, createdTime=Tue May 14 00:46:00 CST 2019, time=2019-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1557078, encodeId=39cb155e0789a, content=<a href='/topic/show?id=154be128170' target=_blank style='color:#2F92EE;'>#癌变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71281, encryptionId=154be128170, topicName=癌变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cd7914850828, createdName=axin014, createdTime=Mon Mar 25 09:46:00 CST 2019, time=2019-03-25, status=1, ipAttribution=)]
    2019-05-18 yzh409
  3. [GetPortalCommentsPageByObjectIdResponse(id=2041381, encodeId=42282041381a7, content=<a href='/topic/show?id=baade55002a' target=_blank style='color:#2F92EE;'>#突变型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75500, encryptionId=baade55002a, topicName=突变型)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Sat Sep 28 08:46:00 CST 2019, time=2019-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1696333, encodeId=2265169633385, content=<a href='/topic/show?id=0107934e0a5' target=_blank style='color:#2F92EE;'>#转运#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93470, encryptionId=0107934e0a5, topicName=转运)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=47c429881595, createdName=yzh409, createdTime=Sat May 18 19:46:00 CST 2019, time=2019-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2036555, encodeId=79b820365556c, content=<a href='/topic/show?id=672b1e7029e' target=_blank style='color:#2F92EE;'>#TpoR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17702, encryptionId=672b1e7029e, topicName=TpoR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=69cb413, createdName=chengjn, createdTime=Mon Feb 24 03:46:00 CST 2020, time=2020-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1719432, encodeId=87781e1943229, content=<a href='/topic/show?id=72b8963e392' target=_blank style='color:#2F92EE;'>#钙网蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96373, encryptionId=72b8963e392, topicName=钙网蛋白)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=079632715693, createdName=nian.wang1993, createdTime=Tue May 14 00:46:00 CST 2019, time=2019-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1557078, encodeId=39cb155e0789a, content=<a href='/topic/show?id=154be128170' target=_blank style='color:#2F92EE;'>#癌变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71281, encryptionId=154be128170, topicName=癌变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cd7914850828, createdName=axin014, createdTime=Mon Mar 25 09:46:00 CST 2019, time=2019-03-25, status=1, ipAttribution=)]
    2020-02-24 chengjn
  4. [GetPortalCommentsPageByObjectIdResponse(id=2041381, encodeId=42282041381a7, content=<a href='/topic/show?id=baade55002a' target=_blank style='color:#2F92EE;'>#突变型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75500, encryptionId=baade55002a, topicName=突变型)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Sat Sep 28 08:46:00 CST 2019, time=2019-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1696333, encodeId=2265169633385, content=<a href='/topic/show?id=0107934e0a5' target=_blank style='color:#2F92EE;'>#转运#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93470, encryptionId=0107934e0a5, topicName=转运)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=47c429881595, createdName=yzh409, createdTime=Sat May 18 19:46:00 CST 2019, time=2019-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2036555, encodeId=79b820365556c, content=<a href='/topic/show?id=672b1e7029e' target=_blank style='color:#2F92EE;'>#TpoR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17702, encryptionId=672b1e7029e, topicName=TpoR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=69cb413, createdName=chengjn, createdTime=Mon Feb 24 03:46:00 CST 2020, time=2020-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1719432, encodeId=87781e1943229, content=<a href='/topic/show?id=72b8963e392' target=_blank style='color:#2F92EE;'>#钙网蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96373, encryptionId=72b8963e392, topicName=钙网蛋白)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=079632715693, createdName=nian.wang1993, createdTime=Tue May 14 00:46:00 CST 2019, time=2019-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1557078, encodeId=39cb155e0789a, content=<a href='/topic/show?id=154be128170' target=_blank style='color:#2F92EE;'>#癌变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71281, encryptionId=154be128170, topicName=癌变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cd7914850828, createdName=axin014, createdTime=Mon Mar 25 09:46:00 CST 2019, time=2019-03-25, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=2041381, encodeId=42282041381a7, content=<a href='/topic/show?id=baade55002a' target=_blank style='color:#2F92EE;'>#突变型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75500, encryptionId=baade55002a, topicName=突变型)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Sat Sep 28 08:46:00 CST 2019, time=2019-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1696333, encodeId=2265169633385, content=<a href='/topic/show?id=0107934e0a5' target=_blank style='color:#2F92EE;'>#转运#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93470, encryptionId=0107934e0a5, topicName=转运)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=47c429881595, createdName=yzh409, createdTime=Sat May 18 19:46:00 CST 2019, time=2019-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2036555, encodeId=79b820365556c, content=<a href='/topic/show?id=672b1e7029e' target=_blank style='color:#2F92EE;'>#TpoR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17702, encryptionId=672b1e7029e, topicName=TpoR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=69cb413, createdName=chengjn, createdTime=Mon Feb 24 03:46:00 CST 2020, time=2020-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1719432, encodeId=87781e1943229, content=<a href='/topic/show?id=72b8963e392' target=_blank style='color:#2F92EE;'>#钙网蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96373, encryptionId=72b8963e392, topicName=钙网蛋白)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=079632715693, createdName=nian.wang1993, createdTime=Tue May 14 00:46:00 CST 2019, time=2019-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1557078, encodeId=39cb155e0789a, content=<a href='/topic/show?id=154be128170' target=_blank style='color:#2F92EE;'>#癌变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71281, encryptionId=154be128170, topicName=癌变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cd7914850828, createdName=axin014, createdTime=Mon Mar 25 09:46:00 CST 2019, time=2019-03-25, status=1, ipAttribution=)]
    2019-03-25 axin014

相关资讯

钙网蛋白(calreticulin)与肿瘤免疫的研究

存的场所,各种内外源性损伤均可导致内质网折叠功能紊乱,引起内质网应激。许多肿瘤都可以观察到内质网应激。在内质网应激情况下,内质网分子伴侣糖调节蛋白GRP78 与重链结合蛋白Bip 表达水平上调,通过多种机制使肿瘤生长,与肿瘤的演进、耐药性甚至转移有关[1] ;而新近研究发现,内质网钙结合蛋白钙网蛋白(calreticulin,CRT) 在内质网应激情况下,能诱导免疫原性细胞凋亡,引发肿瘤免疫[2]

Blood:在骨髓增生性肿瘤中,突变型钙网蛋白与MPL之间的致病性的相互作用。

钙网蛋白(CALR)突变是骨髓增生性肿瘤(MPN)的发病机制中的表型驱动因素。机械论学说已证实突变的CALR与血小板生成素受体MPL结合,突变型CALR介导激活JAK-STAT信号通路需要突变型CALR C末端的正电荷。研究人员发现,虽然突变型CALR和MPL结合对于突变型CALR转化造血细胞是必需的,但只有该结合对细胞因子独立生长又是不够的。突变型CALR C末端的正电荷的阈值会影响突变CALR